ArticleJournal of virology1999
Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 125 citations in OpenAlex.
- A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.Vaccine · 2023Article
- Immunogenic Properties and Antigenic Similarity of Virus-like Particles Derived from Human Polyomaviruses.International journal of molecular sciences · 2023Article
- Carbohydrates: Binding Sites and Potential Drug Targets for Neural-Affecting Pathogens.Advances in neurobiology · 2023Article
- Trafficking of JC virus-like particles across the blood-brain barrier.Nanoscale advances · 2021Article
- Comparative Evaluation of Human Papillomavirus Type 16 L1 Protein Expressed in Plasmid- and Baculovirus-Based Systems in Insect Cells.Archives of Razi Institute · 2020Article
- Gene therapy for castration-resistant prostate cancer cells using JC polyomavirus-like particles packaged with a PSA promoter driven-suicide gene.Cancer gene therapy · 2019Article
- Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector.Scientific reports · 2018Article
- Effects of Repeated Ropinirole Treatment on Phencyclidine-Induced Hyperlocomotion, Prepulse Inhibition Deficits, and Social Avoidance in Rats.The Journal of pharmacology and experimental therapeutics · 2017Article
- The application of virus-like particles as vaccines and biological vehicles.Applied microbiology and biotechnology · 2015Review
- Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene.Journal of translational medicine · 2015Article
- Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors.Frontiers in immunology · 2015Review
- Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- The human fetal glial cell line SVG p12 contains infectious BK polyomavirus.Journal of virology · 2014Article
- Efficient uptake of blood-borne BK and JC polyomavirus-like particles in endothelial cells of liver sinusoids and renal vasa recta.PloS one · 2014Article
- T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors.Journal of virology · 2013Article
- Review
- Virus-like particles: the new frontier of vaccines for animal viral infections.Veterinary immunology and immunopathology · 2012Review
- Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity.The Journal of infectious diseases · 2011Article
- Baculovirus expression systems for production of recombinant proteins in insect and mammalian cells.Molecular biology · 2011Article
- Engineered biological entities for drug delivery and gene therapy protein nanoparticles.Progress in molecular biology and translational science · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major structural viral protein, VP1, of the human polyomavirus JC virus (JCV), the causative agent of progressive multifocal leukoencephalopathy (PML), was expressed by using recombinant baculoviruses. Recombinant VP1 formed virus-like particles (VLP) with the typical morphology of empty JCV capsids. Purified VP1 VLP bind to SVG, B, and T cells, as well as to monkey kidney cells. After binding, VP1 VLP were also internalized with high efficiency and transported to the nucleus. Immunization studies revealed these particles as highly immunogenic when administered with adjuvant, while immunization without adjuvant induced no immune response. VP1 VLP hyperimmune serum inhibits binding to SVG cells and neutralizes natural JCV. Furthermore, the potential of VP1 VLP as an efficient transporter system for gene therapy was demonstrated. Exogenous DNA could be efficiently packaged into VP1 VLP, and the packaged DNA was transferred into COS-7 cells as shown by the expression of a marker gene. Thus, VP1 VLP are useful for PML vaccine development and represent a potential new transporter system for human gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.